Gupta Umesh, Sharma Saurabh, Khan Iliyas, Gothwal Avinash, Sharma Ashok K, Singh Yuvraj, Chourasia Manish K, Kumar Vipin
Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandar Sindri, Ajmer, Rajasthan, 305817, India.
Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandar Sindri, Ajmer, Rajasthan, 305817, India.
Int J Biol Macromol. 2017 May;98:810-819. doi: 10.1016/j.ijbiomac.2017.02.030. Epub 2017 Feb 9.
Taxanes have established and proven effectivity against different types of cancers; in particular breast cancers. However, the high hemolytic toxicity and hydrophobic nature of paclitaxel and docetaxel have always posed challenges to achieve safe and effective delivery. Use of bio-degradable materials with an added advantage of nanotechnology could possibly improve the condition so as to achieve better and safe delivery. In the present study paclitaxel loaded chitosan nanoparticles were formulated and optimized using simple w/o nanoemulsion technique. The observed average size, pdi, zeta potential, entrapment efficiency and drug loading for the optimized paclitaxel loaded chitosan nanoparticle formulation (PTX-CS-NP-10) was 226.7±0.70nm, 0.345±0.039, 37.4±0.77mV, 79.24±2.95% and 11.57±0.81%; respectively. Nanoparticles were characterized further for size by Transmission Electron Microscopy (TEM). In vitro release studies exhibited sustained release pattern and more than 60% release was observed within 24h. Enhanced in vitro anticancer activity was observed as a result of MTT assay against triple negative MDA-MB-231 breast cancer cell lines. The observed IC values obtained for PTX-CS-NP-10 was 9.36±1.13μM and was almost 1.6 folds (p<0.05) less than the pure drug. Similarly, PTX-CS-NP-10 were extremely biocompatible and safe as observed for haemolytic toxicity which was almost 4 folds less (p<0.05) than the naïve drug. Anticancer activity was further evaluated using flow cytometry for apoptosis. Cell apoptosis study revealed that PTX-CS-NP-10 treatment resulted into enhanced (almost double) late cell apoptosis than naïve paclitaxel. Hence the developed nanoparticulate formulation not only reduced the overall toxicity but also resulted into improved anticancer efficacy of paclitaxel. It can be concluded that a robust, stable and comparatively safe nanoformulation of paclitaxel was developed, characterized and evaluated.
紫杉烷类药物已被证实对不同类型的癌症,尤其是乳腺癌有效。然而,紫杉醇和多西他赛的高溶血毒性和疏水性一直对实现安全有效的给药构成挑战。使用具有纳米技术附加优势的可生物降解材料可能会改善这种情况,从而实现更好、更安全的给药。在本研究中,采用简单的油包水纳米乳液技术制备并优化了负载紫杉醇的壳聚糖纳米颗粒。优化后的负载紫杉醇的壳聚糖纳米颗粒制剂(PTX-CS-NP-10)的平均粒径、多分散指数、zeta电位、包封率和载药量分别为226.7±0.70nm、0.345±0.039、37.4±0.77mV、79.24±2.95%和11.57±0.81%。通过透射电子显微镜(TEM)对纳米颗粒的尺寸进行了进一步表征。体外释放研究显示出缓释模式,在24小时内观察到超过60%的释放。通过MTT法对三阴性MDA-MB-231乳腺癌细胞系进行体外抗癌活性检测,结果显示活性增强。PTX-CS-NP-10的IC值为9.36±1.13μM,几乎比纯药物低1.6倍(p<0.05)。同样,PTX-CS-NP-10具有极高的生物相容性和安全性,溶血毒性几乎比单纯药物低4倍(p<0.05)。使用流式细胞术对细胞凋亡进行进一步评估来研究抗癌活性。细胞凋亡研究表明,PTX-CS-NP-10处理导致晚期细胞凋亡比单纯紫杉醇增强(几乎翻倍)。因此,所开发的纳米颗粒制剂不仅降低了总体毒性,还提高了紫杉醇的抗癌疗效。可以得出结论,已开发、表征并评估了一种强大、稳定且相对安全的紫杉醇纳米制剂。